GleamWall
中文EN

INCY INCYTE CORP

Services-Commercial Physical & Biological Research · Nasdaq · SEC CIK 879169 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY24.9%
TTM net income YoY-66.1%
TTM EPS YoY-66.8%
Revenue 3-yr CAGR18.5%
Net income 3-yr CAGR-1.7%

Margins

Gross margin92.7%
Operating margin10.4%
Net margin6.7%
FCF margin—
EBITDA margin12.1%

Returns

ROE7.8%
ROA5.9%
ROIC (approx.)13.9%
Asset turnover0.88x

Leverage & solvency

Liabilities / assets22.6%
Debt / equity0.00x
Current ratio3.84x
Interest coverage267.97x

Cash quality & payout

Operating cash flow / net income1.85x
Accruals ratio-5.0%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$1.56B$1.67B$1.27B$1.51B$1.37B$1.22B$1.05B$1.18B
Cost of revenue$108.74M$104.96M$104.52M$121.17M$99.00M$78.77M$73.19M$88.48M
Gross profit$1.45B$1.57B$1.17B$1.39B$1.27B$1.14B$979.71M$1.09B
R&D expense$1.79B$516.95M$515.90M$611.37M$506.58M$494.92M$437.28M$466.03M
SG&A expense$364.27M$351.74M$328.09M$390.41M$329.08M$331.02M$325.69M$326.71M
Operating income-$708.36M$697.90M$301.12M$335.86M$443.52M$530.31M$205.17M$301.51M
Interest expense$605,000$582,000$569,000$582,000$592,000$594,000$660,000$419,000
Pretax income-$688.85M$751.51M$343.60M$389.94M$482.31M$558.01M$234.19M$313.72M
Income tax$95.95M$165.91M$40.27M$90.66M$58.14M$153.01M$75.99M$112.51M
Net income-$784.80M$585.61M$303.33M$299.28M$424.17M$405.00M$158.20M$201.21M
EBITDA-$684.19M$724.37M$324.92M$359.84M$467.54M$553.23M$227.53M$324.25M
EPS (basic)-3.862.921.52—2.172.090.82—
EPS (diluted)-3.862.811.47—2.112.040.80—
Weighted avg. shares (diluted)203.25M208.22M206.83M—201.43M198.74M198.20M—
Balance sheet
Cash & equivalents$3.28B$3.98B$3.46B$3.10B$2.46B$1.96B$1.94B$1.69B
Inventory$134.25M$112.54M$115.62M$101.06M$83.45M$83.42M$63.98M$58.87M
Current assets$5.52B$6.03B$5.48B$5.02B$4.28B$3.64B$3.51B$3.24B
PP&E, net$701.10M$709.47M$720.17M$730.88M$798.63M$798.54M$765.36M$763.41M
Goodwill$133.00M$133.00M$133.00M$133.00M$155.59M$155.59M$155.59M$155.59M
Total assets$7.29B$7.87B$7.34B$6.96B$6.33B$5.82B$5.75B$5.44B
Current liabilities$1.44B$1.31B$1.49B$1.52B$1.34B$1.28B$1.72B$1.64B
Total liabilities$1.64B$1.53B$1.72B$1.79B$1.68B$1.65B$2.08B$2.00B
Shareholders' equity$5.64B$6.34B$5.62B$5.17B$4.65B$4.17B$3.67B$3.45B
Shares outstanding204.00M200.98M199.95M198.46M196.13M194.12M193.78M193.43M
Cash flow statement
Operating cash flow-$675.32M$507.66M$369.35M$543.30M$559.39M$44.74M$266.07M$381.22M
Investing cash flow-$44.34M-$51.79M-$88.20M-$37.42M-$47.42M-$18.87M$1.10M-$21.46M
Financing cash flow$13.94M$65.46M$84.82M$137.74M-$12.78M-$11.25M-$12.68M$20.39M
Depreciation & amortization$24.18M$26.48M$23.80M$23.98M$24.02M$22.92M$22.36M$22.73M
Stock-based compensation$69.80M$67.30M$64.13M$62.16M$61.60M$64.60M$60.98M$71.72M
Share buybacks———$0$0——$0

Free plan shows the latest 8 periods; Pro shows all 67 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.